Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study

Trial Profile

Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Lithium (Primary) ; Temozolomide (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2015 Time Frame for primary endpoint changed from 6 months to 50 months as per NCT.
    • 12 Jan 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 26 Feb 2014 Planned End Date changed from 1 Apr 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top